Clementia Pharmaceuticals Quick Ratio (CMTA) starting from the fourth quarter 2018 to fourth quarter 2017, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Clementia Pharmaceuticals Inc.  (CMTA)

Clementia Pharmaceuticals's Quick Ratio

CMTA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Clementia Pharmaceuticals's Cash & cash equivalent grew by 687.7 % in the Q4 2018 sequentially, faster than Current Liabilities, this led to improvement in Clementia Pharmaceuticals's Quick Ratio to 7.65 a new company high.

Within Major Pharmaceutical Preparations industry 176 other companies have achieved higher Quick Ratio than Clementia Pharmaceuticals in fourth quarter 2018. While Quick Ratio total ranking has improved so far during the Q4 2018 to 818, from total ranking in the third quarter 2018 at 2120.

Explain Quick Ratio?
How much Cash & cash equivalents CMTA´s has?
What are CMTA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CMTA Quick Ratio (Dec 31 2018)
Q4		 (Sep 30 2018)
Q3		 (Jun 30 2018)
Q2		 (Mar 31 2018)
Q1		 (Dec 31 2017)
Q4
Y / Y Current Liabilities Change - - - - -
Y / Y Cash & cash equivalent Change 162.14 % -67.62 % 11.68 % 12.29 % 284.02 %
Quick Ratio MRQ 7.65 1.37 1.53 3.08 -
CMTA's Total Ranking # 818 # 2120 # 2053 # 1362 #
Seq. Current Liabilities Change 41.18 % 3.99 % -2.39 % - -
Seq. Cash & cash equivalent Change 687.7 % -6.8 % -51.43 % -26.47 % -2.71 %



Quick Ratio fourth quarter 2018 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 177
Healthcare Sector # 280
Overall Market # 795


Quick Ratio Statistics
High Average Low
7.65 3.41 1.37
(Dec 31 2018)   (Sep 30 2018)




Financial Statements
Clementia Pharmaceuticals's Current Liabilities $ 12 Millions Visit CMTA's Balance sheet
Clementia Pharmaceuticals's Cash & cash equivalent $ 95 Millions Visit CMTA's Balance sheet
Source of CMTA's Sales Visit CMTA's Sales by Geography


Cumulative Clementia Pharmaceuticals's Quick Ratio

CMTA's Quick Ratio for the trailling 12 Months

CMTA Quick Ratio

 (Dec 31 2018)
12 Months		 (Sep 30 2018)
12 Months		 (Jun 30 2018)
12 Months		 (Mar 31 2018)
12 Months		 (Dec 31 2017)
12 Months
Y / Y Current Liabilities TTM Growth - - - - -
Y / Y Cash & cash equivalent TTM Growth 34.78 % 7.18 % 152.67 % 236.86 % 1052.95 %
Quick Ratio TTM 3.83 3.39 6.6 12.89 -
Total Ranking TTM # 4585 # 0 # 0 # 0 # 0
Seq. Current Liabilities TTM Growth 47.91 % 51.37 % 97.61 % - -
Seq. Cash & cash equivalent TTM Growth 66.86 % -22.28 % 1.21 % 2.68 % 32.69 %

Quick ratio ranking by company, industry and sector >> Back to CMTA Financial Strength Comparisons >> Go to Compare CMTA Quick Ratio to its Competitors

On the trailing twelve months basis CMTA Cash & cash equivalent more than doubled by 162.14 % in Q4 2018 year on year, faster than Current Liabilities, this led to increase in in Clementia Pharmaceuticals's Quick Ratio to 3.83, Quick Ratio remained below CMTA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 429 other companies have achieved higher Quick Ratio than Clementia Pharmaceuticals. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2018 from 0 to 4585.

Explain Quick Ratio?
How much Cash & cash equivalents CMTA´s has?
What are CMTA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 430
Healthcare Sector # 823
Within the Market # 4585


trailing twelve months Quick Ratio Statistics
High Average Low
3.83 3.83 3.83
(Dec 31 2018)  




Companies with similar Quick Ratio in the quarter ending Dec 31 2018, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2018 MRQ Cash & cash equivalentDec 31 2018 MRQ Current Liabilities
Ra Pharmaceuticals Inc   20.57 $ 209.822  Millions$ 10.201  Millions
Mirum Pharmaceuticals Inc   20.26 $ 51.963  Millions$ 2.565  Millions
Innoviva Inc   20.16 $ 114.908  Millions$ 5.700  Millions
Atreca inc   20.05 $ 114.504  Millions$ 5.711  Millions
Crescent Biopharma Inc   20.02 $ 209.970  Millions$ 10.490  Millions
Prothena Corporation Public Limited Company  19.68 $ 427.659  Millions$ 21.727  Millions
Anaptysbio Inc   19.56 $ 427.082  Millions$ 21.836  Millions
Enanta Pharmaceuticals Inc  19.27 $ 308.730  Millions$ 16.025  Millions
Syros Pharmaceuticals Inc   19.13 $ 100.317  Millions$ 5.244  Millions
Global Blood Therapeutics Inc.  18.39 $ 919.599  Millions$ 50.005  Millions
Cryoport inc   18.15 $ 55.558  Millions$ 3.061  Millions
Reviva Pharmaceuticals Holdings Inc   17.90 $ 0.401  Millions$ 0.022  Millions
Arena Pharmaceuticals Inc   17.67 $ 445.631  Millions$ 25.214  Millions
Merus N v   17.40 $ 258.808  Millions$ 14.873  Millions
Boundless Bio Inc   17.37 $ 414.307  Millions$ 23.852  Millions
Oragenics Inc   17.31 $ 20.208  Millions$ 1.168  Millions
China Yct International Group, Inc.  17.15 $ 37.420  Millions$ 2.181  Millions
Neurogene Inc   16.63 $ 76.928  Millions$ 4.627  Millions
Eton Pharmaceuticals Inc   16.59 $ 13.156  Millions$ 0.793  Millions
Milestone Pharmaceuticals Inc   16.44 $ 85.976  Millions$ 5.231  Millions
Tricida Inc   16.28 $ 241.078  Millions$ 14.804  Millions
Nektar Therapeutics  16.28 $ 1,335.350  Millions$ 82.002  Millions
Aurinia Pharmaceuticals Inc   16.25 $ 117.967  Millions$ 7.261  Millions
Y mabs Therapeutics inc   16.21 $ 147.840  Millions$ 9.123  Millions
Evelo Biosciences Inc   16.02 $ 147.919  Millions$ 9.235  Millions
Cnbx Pharmaceuticals Inc   15.94 $ 6.580  Millions$ 0.413  Millions
Assembly Biosciences Inc   15.80 $ 218.080  Millions$ 13.804  Millions
Ideaya Biosciences Inc   15.79 $ 89.961  Millions$ 5.698  Millions
Kineta Inc   15.69 $ 118.379  Millions$ 7.545  Millions
Sol gel Technologies Ltd   15.67 $ 61.987  Millions$ 3.955  Millions

Date modified: 2026-09-05T11:07:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.